Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors.
about
Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YYMolecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinomaEfficient translation of rotavirus mRNA requires simultaneous interaction of NSP3 with the eukaryotic translation initiation factor eIF4G and the mRNA 3' endPolycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155.Rotavirus spike protein VP4 binds to and remodels actin bundles of the epithelial brush border into actin bodies.A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosumSignal transduction of the GLP-1-receptor cloned from a human insulinomaKaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3Molecular pharmacological phenotyping of EBI2. An orphan seven-transmembrane receptor with constitutive activityStable expression of high affinity NK1 (substance P) and NK2 (neurokinin A) receptors but low affinity NK3 (neurokinin B) receptors in transfected CHO cellsThe functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptorThe cloned rat pancreatic polypeptide receptor exhibits profound differences to the orthologous receptorChicken neuropeptide Y receptor Y2: structural and pharmacological differences to mammalian Y2(1).Increased interstitial pressure improves nucleic acid delivery to skin enabling a comparative analysis of constitutive promoters.Generation of an activating Zn(2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle.Mutational analysis of the interaction of the N- and C-terminal ends of angiotensin II with the rat AT(1A) receptorDifferentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.Major histocompatibility complex conformational epitopes are peptide specific.Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4.Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations.Mutational analysis of Lck in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in kinase activity.Determinants essential for the transmissible gastroenteritis virus-receptor interaction reside within a domain of aminopeptidase-N that is distinct from the enzymatic site.Stable transfection of Acanthamoeba.Intracellular accumulation of the amyloidogenic L68Q variant of human cystatin C in NIH/3T3 cells.Influence of second and third cytoplasmic loops on binding, internalization, and coupling of chimeric bombesin/m3 muscarinic receptors.Urokinase-type plasminogen activator receptor is internalized by different mechanisms in polarized and nonpolarized Madin-Darby canine kidney epithelial cells.The human cytomegalovirus US28 protein is located in endocytic vesicles and undergoes constitutive endocytosis and recycling.CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.The coronavirus transmissible gastroenteritis virus causes infection after receptor-mediated endocytosis and acid-dependent fusion with an intracellular compartment.The cytomegalovirus UL146 gene product vCXCL1 targets both CXCR1 and CXCR2 as an agonist.Murine cytomegalovirus (CMV) M33 and human CMV US28 receptors exhibit similar constitutive signaling activities.Gene marking of human neural stem/precursor cells using green fluorescent proteins.Activation of silenced transgene expression in neural precursor cell lines by inhibitors of histone deacetylation.Localization of HCMV UL33 and US27 in endocytic compartments and viral membranes.Symptomatic type 1 protein C deficiency caused by a de novo Ser270Leu mutation in the catalytic domain.Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6.Apical and non-polarized secretion of serpins from MDCK cells.
P2860
Q22008605-2BFE7ADA-DA28-4384-BA28-65E5B09521ACQ24304140-0BAA827D-3254-423F-88B6-6586E4FEB928Q24314426-DB81DECD-A7D9-4362-8055-6D81A145AD83Q24527184-7343C5D1-C93F-466D-B84B-6A2FD6EF2AAAQ24542505-195530AF-E7DE-4304-AD9A-77B17971D650Q24543264-5D453989-5E5E-454B-AA76-F354E56ED162Q28114992-4A4D721F-3E87-479D-BD37-BF95AF69EC48Q28286399-50F1C062-1C8E-4EBA-8AB2-92DF6C4E8CA1Q28296088-C3CE8873-7CF9-4A6E-9F40-DE58A1A1CC31Q28302291-1E29565A-8E28-4D88-9995-292F0F4D64C9Q28343055-EC32D69E-7729-407D-8C55-10FF06F21A93Q28379256-8CBD392A-74D1-4964-BE7B-C8F3A71885DDQ28578355-08F9CA7E-E10A-412C-9C8B-588EE30D01ABQ30962310-9A99BF26-8286-4367-A729-F2E1B7BBBBFAQ33576601-6000A3D1-6B4B-4235-B9EA-6D5088DCAE72Q34010632-6130A21D-6AB7-4A6A-A2FD-CF87BCA2AE31Q35042469-BAB5CB3F-99B8-42B7-BD77-6F794553BFB7Q35611810-54913E38-BCD2-415A-B268-11FC1048D57EQ35872545-F511C343-2C14-4B9B-ACA0-D6999D3D1071Q36232104-911C5AFA-79BA-4FC0-A52C-F5E82ED8C363Q36276570-B0AA4A33-5BAB-4F9D-B460-361A3C767663Q36399333-CA2B3BE3-77E4-4C81-BEBF-0136862A1755Q36424948-7D895A26-5EB8-4B5F-99DE-89CC06EBCCA7Q36562252-6AA081B0-1E8B-4A37-B173-565B94A34D3BQ36625655-B0C51145-264F-44A2-B18F-115FFCE76A50Q36852404-C552FF9D-E668-43DF-81E1-4B5865619725Q37641582-0D780DE8-F22D-4C0B-BD4D-E56CDDFAB2EEQ38293235-C1EA7D6B-0960-4A3A-8545-BC7419F8C45EQ38609665-CF0C7445-50B3-4E34-A9EA-02657E77BD20Q38762028-02D0CB72-4BD0-4461-8037-19637D10146CQ39550956-6E5B6FBF-A1C2-4011-9A7C-2D9F03679E81Q39577308-A4756A2B-73D4-49A8-AD95-58C21BAB228EQ39616316-3727CA83-9506-4045-B301-646C694DAAD3Q39753137-C192BBF4-C6A9-4935-85EB-55D6E5DA230CQ40499382-1994D6D8-1FA9-457D-BA11-592AE8543ABFQ40718965-E55FC420-CEC6-4A27-A9CD-622B5EC73EBDQ40745525-B59E78BF-A274-4B42-9F4F-78FBA5EC46ADQ40802639-F0E10BD0-DA18-445F-B453-56732C757D9BQ40803165-B3CF0F85-9B06-489F-98C6-87CD2FC9DA6EQ40878809-2852F77D-EA33-466B-8412-AE0729E79C70
P2860
Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Biosynthesis of peptide precur ...... eukaryotic expression vectors.
@en
Biosynthesis of peptide precur ...... eukaryotic expression vectors.
@nl
type
label
Biosynthesis of peptide precur ...... eukaryotic expression vectors.
@en
Biosynthesis of peptide precur ...... eukaryotic expression vectors.
@nl
prefLabel
Biosynthesis of peptide precur ...... eukaryotic expression vectors.
@en
Biosynthesis of peptide precur ...... eukaryotic expression vectors.
@nl
P2093
P2860
P1433
P1476
Biosynthesis of peptide precur ...... eukaryotic expression vectors
@en
P2093
Johansen TE
Schøller MS
P2860
P304
P356
10.1016/0014-5793(90)80947-H
P407
P577
1990-07-01T00:00:00Z